Trial reportThe Journal of infectious diseases2018
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.
Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02378753 ([rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
[rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.Emerging infectious diseases · 2020Trial
- Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.The Journal of infectious diseases · 2019Trial
- Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.The Journal of infectious diseases · 2018Trial
- Informing life-course immunization and pandemic preparedness: a COVID-19 vaccine evaluation and HPV introduction experience in Sierra Leone.BMC public health · 2026Article
- From Product Availability to Population Protection: Vaccine Deployment Readiness in Sierra Leone.Annals of global health · 2026Article
- Article
- Article
- Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.Viruses · 2025Article
- Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.Clinical and experimental immunology · 2025Review
- Translational success of fundamental virology: a VSV-vectored Ebola vaccine.Journal of virology · 2024Review
- Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.Vaccines · 2024Article
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Review
- Low Prevalence of Deletions of the pfhrp2 and pfhrp3 Genes in Plasmodium falciparum Parasites in Freetown, Sierra Leone in 2015.The American journal of tropical medicine and hygiene · 2022Article
- Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Frontiers in immunology · 2022Review
- Article
- Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein.The Journal of infectious diseases · 2021Article
- Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.Current opinion in virology · 2021Review
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
32 authors.
Mohamed SamaiCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Jane F SewardCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Susan T GoldsteinCenters for Disease Control and Prevention, Atlanta, Georgia.
Barbara E MahonCenters for Disease Control and Prevention, Atlanta, Georgia.
Durodami Radcliffe LiskCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Marc-Alain WiddowsonCenters for Disease Control and Prevention, Atlanta, Georgia.
Mohamed I JallohCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Stephanie J SchragCenters for Disease Control and Prevention, Atlanta, Georgia.
Ayesha IdrissCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Rosalind J CarterCenters for Disease Control and Prevention, Atlanta, Georgia.
Peter DawsonThe Emmes Corporation, Rockville, Maryland.
S A S KargboCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Bailah LeighCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Mohamed BawohCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Jennifer Legardy-WilliamsCenters for Disease Control and Prevention, Atlanta, Georgia.
Gibrilla DeenCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Wendy CarrCenters for Disease Control and Prevention, Atlanta, Georgia.
Amy CallisCenters for Disease Control and Prevention, Atlanta, Georgia.
Robert LindbladThe Emmes Corporation, Rockville, Maryland.
James B W RussellCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Carey R PetrieThe Emmes Corporation, Rockville, Maryland.
Augustin E FombahCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Brima KargboMinistry of Health and Sanitation, Sierra Leone.
Wendi McDonaldCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Olamide D JarrettCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Robert E WalkerBiomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC.
Paul GargiulloCenters for Disease Control and Prevention, Atlanta, Georgia.
Donald Bash-TaqiCollege of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone.
Laura GibsonBiomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC.
Abu Bakarr FofanahMinistry of Health and Sanitation, Sierra Leone.
Anne SchuchatCenters for Disease Control and Prevention, Atlanta, Georgia.
STRIVE Study Team
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical Trials Registration: ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220].
Indexed as
EpidemicsAdolescentAdultAgedDrug-Related Side Effects and Adverse ReactionsEbola VaccinesFemaleHemorrhagic Fever, EbolaHumansLongitudinal StudiesMaleMiddle AgedSierra LeoneVaccines, SyntheticYoung AdultEbola VaccinesVaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02378753ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.